Industry story
GLP-1 Drug Dropout Is High; Cycling On and Off Worsens Body Composition
diet-nutrition drug-treatment hormone-health medication-safety
Dr. Chris Thompson reports that more than one million people per month stop taking GLP-1 drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro), with about 30% stopping within the first month and roughly 50% stopping within a year. Reasons include nausea at higher doses, muscle loss, needle fatigue, and concern about long-term effects of super-physiologic (far above natural) GLP-1 levels. A particular risk Thompson highlights is cycling on and off: when people stop a GLP-1 drug and regain weight, they put back fat but not the lean muscle mass they lost — roughly a third of weight lost on semaglutide is lean mass. Repeated cycles progressively shift body composition toward more fat and less muscle. His clinical recommendation is to taper to a microdose (a self-adjusted lower dose using an insulin syringe) for maintenance rather than stopping entirely, or to bridge to a procedural treatment. Anyone considering GLP-1 drugs who has low muscle mass should get a DEXA scan first and prioritize resistance training throughout.
Full analysis
Dr. Chris Thompson reports that more than one million people per month stop taking GLP-1 drugs such as semaglutide (Ozempic) and tirzepatide (Mounjaro), with about 30% stopping within the first month and roughly 50% stopping within a year. Reasons include nausea at higher doses, muscle loss, needle fatigue, and concern about long-term effects of super-physiologic (far above natural) GLP-1 levels. A particular risk Thompson highlights is cycling on and off: when people stop a GLP-1 drug and regain weight, they put back fat but not the lean muscle mass they lost — roughly a third of weight lost on semaglutide is lean mass. Repeated cycles progressively shift body composition toward more fat and less muscle. His clinical recommendation is to taper to a microdose (a self-adjusted lower dose using an insulin syringe) for maintenance rather than stopping entirely, or to bridge to a procedural treatment. Anyone considering GLP-1 drugs who has low muscle mass should get a DEXA scan first and prioritize resistance training throughout.
Comments